Tim D van Balkom

Has grant

Health care psychologist

Amsterdam University Medical Centers
Country flagNetherlands

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Close

Neurostimulation for the treatment of mild cognitive impairment in Parkinson’s disease: an acceptability cross-over study

Open Date: 2024-06-01

Close Date:

Grant: Close

Personalized treatment of cognitive impairment in Parkinson’s disease

Open Date:

Close Date:

Articles (6)

The adoption of open science principles for data has been instrumental in enabling the creation and reuse of large datasets and efficient collaboration, but requires a dedicated open data sharing infrastructure. Although clinical neuroscience research increasingly involves large-scale collaboration on controlled, sensitive data, open science principles can bring key benefits in this setting. The unique privacy and access requirements of clinical research create challenges that require a specialized data infrastructure, focused on local governance. Here we present a narrative account of a pilot project to establish such an infrastructure for the data of the ENIGMA Parkinson’s Disease working group by adopting the decentralized Nipoppy and Neurobagel tool stack. Our collaboration has led to the adoption of community data standards among international sites of the working group and has launched an open portal that enables the cross-site discovery of cohorts based on harmonized metadata. We discuss our approach to this collaboration, the social and technical challenges we have encountered and how we addressed them in the hope that groups in similar situations may benefit from our experiences.

Year:

2025

Background Impulse control disorders (ICD) in Parkinson’s disease (PD) patients mainly occur as adverse effects of dopamine replacement therapy. Despite several known risk factors associated with ICD development, this cannot yet be accurately predicted at PD diagnosis. Objectives We aimed to investigate the predictability of incident ICD by baseline measures of demographic, clinical, dopamine transporter single photon emission computed tomography (DAT-SPECT), and genetic variables. Methods We used demographic and clinical data of medication-free PD patients from two longitudinal datasets; Parkinson’s Progression Markers Initiative (PPMI) (n=311) and Amsterdam UMC (n=72). We extracted radiomic and latent features from DAT-SPECT. We used single nucleotic polymorphisms (SNPs) from PPMI’s NeuroX and Exome sequencing data. Four machine learning classifiers were trained on combinations of the input feature sets, to predict incident ICD at any follow-up assessment. Classification performance was measured with 10×5-fold cross-validation. Results ICD prevalence at any follow-up was 0.32. The highest performance in predicting incident ICD (AUC=0.66) was achieved by the models trained on clinical features only. Anxiety severity and age of PD onset were identified as the most important features. Performance did not improve with adding features from DAT-SPECT or SNPs. We observed significantly higher performance (AUC=0.74) when classifying patients who developed ICD within four years from diagnosis compared with those tested negative for seven or more years. Conclusions Prediction accuracy for later ICD development, at the time of PD diagnosis, is limited; however, it increases for shorter time-to-event predictions. Neither DAT-SPECT nor genetic data improve the predictability obtained using demographic and clinical variables alone.

Year:

2025

Parkinson’s disease (PD) is associated with extensive structural brain changes. Recent work has proposed that the spatial pattern of disease pathology is shaped by both network spread and local vulnerability. However, only few studies assessed these biological frameworks in large patient samples across disease stages. Analyzing the largest imaging cohort in PD to date (N = 3,096 patients), we investigated the roles of network architecture and local brain features by relating regional abnormality maps to normative profiles of connectivity, intrinsic networks, cytoarchitectonics, neurotransmitter receptor densities, and gene expression. We found widespread cortical and subcortical atrophy in PD to be associated with advancing disease stage, longer time since diagnosis, and poorer global cognition. Structural brain connectivity best explained cortical atrophy patterns in PD and across disease stages. These patterns were robust among individual patients. The precuneus, lateral temporal cortex, and amygdala were identified as likely network-based epicentres, with high convergence across disease stages. Individual epicentres varied significantly among patients, yet they consistently localized to the default mode and limbic networks. Furthermore, we showed that regional overexpression of genes implicated in synaptic structure and signalling conferred increased susceptibility to brain atrophy in PD. In summary, this study demonstrates in a well-powered sample that structural brain abnormalities in PD across disease stages and within individual patients are influenced by both network spread and local vulnerability.

Year:

2025

Non-pharmacological interventions, including cognitive-behavioral therapy (CBT), non-invasive brain stimulation (NIBS), electroconvulsive therapy (ECT), light therapy (LT), and physical rehabilitation/exercise, have shown promise as effective approaches to treat symptoms of depression and anxiety in individuals with Parkinson’s disease (PD). In this narrative literature overview, we discuss the state-of-the-art regarding these treatment options and address future perspectives for clinical practice and research. Non-pharmacological interventions hold promise to treat depression and anxiety in PD. There is meta-analytic evidence for the efficacy of CBT, NIBS, ECT, LT, and exercise on improving depressive symptoms. For the treatment of anxiety symptoms, CBT shows large effects but scientific evidence of other non-pharmacological interventions is limited. Importantly, these treatments are safe interventions with no or mild side-effects. More research is needed to tailor treatment to the individuals’ needs and combined interventions may provide synergistic effects.We conclude that non-pharmacological interventions should be considered as alternative or augmentative treatments to pharmacological and neurosurgical approaches for the treatment of depression and anxiety in individuals with PD.

Year:

2024

Year:

2023

Year:

2023

Collaborators (18)

Christian Rummel

Professor AI Medical Systems

Deggendorf Institute of Technology

GERMANY
View details

Corey McMillan

Associate Professor

University of Pennsylvania

UNITED STATES
View details

Benjamin Newman

University of Virginia

UNITED STATES
View details

Nikhil Bhagwat

McGill University

CANADA
View details

Guido van Wingen

Professor of Neuroimaging in Psychiatry

Amsterdam UMC

NETHERLANDS
View details

Kathleen L. Poston

Associate Professor

Stanford University

UNITED STATES
View details

Ysbrand van der Werf

Professor of Functional Neuroanatomy

Amsterdam UMC

NETHERLANDS
View details

Daniel Weintraub

Professor, Clinician-Educator

University of Pennsylvania

UNITED STATES
View details

Fernando Cendes

Full Professor

University of Campinas

BRAZIL
View details

Chris Vriend

assistant professor

VU University Medical Center

NETHERLANDS
View details

Rick C Helmich

Principle Investigator

Radboud University Medical Center

NETHERLANDS
View details

Philip Mosley

Commonwealth Scientific and Industrial Research Organisation

AUSTRALIA
View details

Gaëtan Garraux

Prof

University of Liege

BELGIUM
View details

Odile van den Heuvel

psychiatrist / full professor

Haukeland University Hospital

NORWAY
View details

Laura M. Parkes

The University of Manchester

UNITED KINGDOM
View details

Mark Hirsch

Professor

Wake Forest School of Medicine

UNITED STATES
View details

Jean-Baptiste Poline

McGill University

CANADA
View details

Alain Dagher

Professor

McGill University

CANADA
View details